Gain Therapeutics Reports Durable Clinical Data for GT-02287 and Advances Novel Parkinson’s Candidate — Gain Therapeutics, Inc.

Event summary

Phase 1b data for GT-02287 shows durable MDS-UPDRS score stability at 150 days, with 6.7-point difference between high and low GluSph baseline groups.
New biomarker analysis reveals reduced DDC levels in high GluSph patients after 90 days of GT-02287 treatment.
Novel chemical series GT-04686 ready for IND-enabling studies for Parkinson’s and other neurological disorders.
16 of 19 Phase 1b participants continued into nine-month extension, supporting GT-02287 tolerability.

The big picture

Gain Therapeutics' data suggests GT-02287 may be the first disease-modifying therapy for Parkinson’s, targeting GCase dysfunction. The company’s Magellan platform continues to generate novel candidates, positioning it as a key player in neurodegenerative disease treatment. Success in this space could validate allosteric modulation as a viable therapeutic approach.

What we're watching

Clinical Validation: Whether the durable MDS-UPDRS results at 150 days will translate into Phase 2 efficacy endpoints.
Pipeline Progression: The pace at which GT-04686 advances through IND-enabling studies and into clinical trials.
Biomarker Strategy: How Gain Therapeutics leverages the GluSph and DDC biomarker data to differentiate GT-02287 in competitive Parkinson’s landscape.